April 29 (Bloomberg) -- GlaxoSmithKline Plc’s $2.6 billion offer for Human Genome Sciences Inc. “completely undervalues” the company according to a major shareholder, the Sunday Times reported.
Mark Evans from Taube Hodson Stonex Partners LLP, a fund manager that owns 5.6 percent of the U.S. drugs maker, termed the bid “unacceptable,” the London-based newspaper said.
Human Genome rejected Glaxo’s $13-a-share cash offer on April 19.
To contact the reporter on this story: Lucy Meakin in London at firstname.lastname@example.org
To contact the editor responsible for this story: Daniel Tilles at email@example.com